Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CARD11-BCL10-MALT1 complex inhibitor XL114

An orally bioavailable inhibitor of the caspase recruitment domain-containing protein 11 (CARD11; CARMA1)-B-cell lymphoma/leukemia 10 (BCL10)-mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) complex, with potential antineoplastic activity. Upon oral administration, CARD11-BCL10-MALT1 complex inhibitor XL114 inhibits the CARD11-BCL10-MALT1 complex and the CARD11-BCL10-MALT1 signaling pathway. This prevents the proliferation of susceptible cancer cells. The CARD11-BCL10-MALT1 signaling pathway promotes B- and T-cell lymphoma survival and proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:CARD11-BCL10-MALT1 pathway inhibitor XL114
CARMA1-BCL10-MALT1 pathway inhibitor XL114
Code name:AUR 104
AUR-104
AUR104
XL 114
XL-114
XL114
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search